Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan,
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Chemotherapy. 2021;66(3):58-64. doi: 10.1159/000517244. Epub 2021 Jul 20.
Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established as first-line treatment, but they have not been confirmed as second-line treatment after FFX. The aim of this study was to evaluate the safety and efficacy of GnP as second-line therapy after FFX in patients with unresectable pancreatic cancer.
Twenty-five patients with unresectable pancreatic cancer were enrolled. The patients were treated with GnP after FFX between September 2015 and September 2019. Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events were evaluated.
The response rate, disease control rate, median PFS, and median OS were 12%, 96%, 5.3 months, and 15.6 months, respectively. The common grade 3 or 4 adverse events were neutropenia (76%) and anemia (16%).
GnP after FOLFIRINOX is expected to be one of the second-line recommendations for patients with unresectable pancreatic cancer.
晚期胰腺癌患者预后较差。FOLFIRINOX（FFX）和吉西他滨加 nab-紫杉醇（GnP）已被确立为一线治疗方法，但尚未被确认为 FFX 后的二线治疗方法。本研究旨在评估 GnP 作为不可切除胰腺癌患者 FFX 后的二线治疗的安全性和有效性。
2015 年 9 月至 2019 年 9 月期间，共纳入 25 例不可切除的胰腺癌患者，接受 GnP 治疗。评估肿瘤反应、无进展生存期（PFS）、总生存期（OS）和不良事件发生率。
有效率、疾病控制率、中位 PFS 和中位 OS 分别为 12%、96%、5.3 个月和 15.6 个月。常见的 3 级或 4 级不良事件为中性粒细胞减少（76%）和贫血（16%）。
FFX 后 GnP 有望成为不可切除胰腺癌患者的二线推荐之一。
